Literature DB >> 23474119

Peritoneal fluid concentrations of β-chemokines in endometriosis.

Kalliopi-Maria Margari1, Alexandros Zafiropoulos, Eleftheria Hatzidaki, Christina Giannakopoulou, Aydin Arici, Ioannis Matalliotakis.   

Abstract

OBJECTIVE: To examine whether the levels of MCP-1, RANTES and MCP-3 in the peritoneal fluid correlate with endometriosis. STUDY
DESIGN: Patients with endometriosis were compared with controls.
SETTING: Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, CT, USA.
SUBJECTS: This study involved 95 women of reproductive age who were undergoing laparoscopy for evaluation of infertility or for pelvic pain. They were divided into an endometriosis group (n=54) and a control group (n=41).
INTERVENTIONS: Peritoneal fluid samples were obtained and β-chemokines (MCP-1, RANTES and MCP-3) were measured using ELISA. STATISTICAL ANALYSIS: Mean and median values were used to present values. Due to the non-normality of chemokines, a log transformation was applied. Differences were examined using independent samples t-test. One-way ANOVA and Tukey HSD multiple comparison post hoc tests were applied. A significance level at 0.05 was set.
RESULTS: The levels of MCP-1 are higher (p for log values=0.024) in the control group (mean=687.6, SD=467.7 pg/ml) than those of the endometriosis group (mean=570.4, SD=633.1 pg/ml). The same is true for the median values of MCP-1 (control median=568.5, endometriosis median=384.7 pg/ml). MCP-3 and RANTES do not differ significantly (MCP-3 p=0.787, RANTES p=0.153). The levels of MCP-1 in patients with stage II endometriosis are significantly lower in comparison with stage III (p=0.048) and stage IV (p=0.033) endometriosis.
CONCLUSIONS: A decrease in the concentrations of MCP-1 in stage I endometriosis has been observed, which is even larger in stage II, in contrast to stage III and stage IV endometriosis, which exhibit concentrations similar to the controls.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23474119     DOI: 10.1016/j.ejogrb.2013.02.010

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  5 in total

Review 1.  Endometriosis: where are we and where are we going?

Authors:  Alexis D Greene; Stephanie A Lang; Jessica A Kendziorski; Julie M Sroga-Rios; Thomas J Herzog; Katherine A Burns
Journal:  Reproduction       Date:  2016-05-10       Impact factor: 3.906

2.  Aberrant Endometrial DNA Methylome and Associated Gene Expression in Women with Endometriosis.

Authors:  Sahar Houshdaran; Camran R Nezhat; Kim Chi Vo; Zara Zelenko; Juan C Irwin; Linda C Giudice
Journal:  Biol Reprod       Date:  2016-08-17       Impact factor: 4.285

Review 3.  Ethiopathogenic mechanisms of endometriosis-related infertility.

Authors:  Michele Gomes Da Broi; Rui Alberto Ferriani; Paula Andrea Navarro
Journal:  JBRA Assist Reprod       Date:  2019-08-22

4.  Expression levels of MCP-1, HGF, and IGF-1 in endometriotic patients compared with non-endometriotic controls.

Authors:  Sahel Heidari; Roya Kolahdouz-Mohammadi; Sepideh Khodaverdi; Nader Tajik; Ali-Akbar Delbandi
Journal:  BMC Womens Health       Date:  2021-12-20       Impact factor: 2.809

5.  Curcumin attenuates proangiogenic and proinflammatory factors in human eutopic endometrial stromal cells through the NF-κB signaling pathway.

Authors:  Indrajit Chowdhury; Saswati Banerjee; Adel Driss; Wei Xu; Sherifeh Mehrabi; Ceana Nezhat; Neil Sidell; Robert N Taylor; Winston E Thompson
Journal:  J Cell Physiol       Date:  2018-09-27       Impact factor: 6.384

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.